STANDARD OPERATING

PROCEDURE –
TRANSPORTATION OF COVID-19
VACCINES:
Pfizer BioNTech and Moderna Vaccines

Department of Health
Public Health New Brunswick
November 2021
TABLE OF CONTENTS
INTRODUCTION ........................................................................................................................................... 1
PURPOSE ..................................................................................................................................................... 1
1. PROCESS ................................................................................................................................................. 1
Planning Principles ........................................................................................................................ 1
1.1. Storage Requirements for COVID Vaccines ......................................................................... 2
1.2. Guidelines for Redistribution ................................................................................................. 4
2. RECOMMENDATIONS FOR ONWARD TRANSPORTATION ................................................................ 6
2.1. Packing for Just in time Use .................................................................................................. 6
2.2. How to Pack an Insulated Cooler ........................................................................................... 7
2.3. Transportation to and arrival at clinic site ............................................................................ 7
2.4. Receipt of the vaccine ............................................................................................................. 8
2.5. Temperature excursions ......................................................................................................... 8
RESOURCES ................................................................................................................................................ 9
APPENDIX A – PACKING INSTRUCTIONS SMALL ................................................................................ 10
APPENDIX B – PACKING INSTRUCTIONS MEDIUM .............................................................................. 13
APPENDIX C – TEMP TALES IMINI USB PHARMA ................................................................................ 15
APPENDIX D – TRANSPORTER REGISTER COVID-19 VACCINES ...................................................... 16
APPENDIX E – RECEIVER REGISTER COVID-19 VACCINES ............................................................... 17
APPENDIX F – PUBLIC HEALTH COMMUNICABLE DISEASE TEAM CONTACT LIST ....................... 18

i November 2021
TRANSPORTATION OF COVID-19 VACCINES

INTRODUCTION
Pfizer does not recommend redistribution of Pfizer BioNTech’s COVID-19 vaccine as part of regular
operations because of increased risks to the vaccine. Moderna states that the Moderna COVID-19 vaccine
should be shipped in the frozen state at -25°C to -15°C and should not be shipped or stored below -40°C.
Understanding that redistribution may be required and encouraged by local regulatory authorities, both
Pfizer BioNTech and Moderna have provided guidance to reduce the risks to the vaccine during
redistribution at 2°C to 8°C.
Movement of the vaccine is permitted in New Brunswick under strict conditions. Information is based on
Pfizer’s Redistribution Considerations for Pfizer-BioNTech COVID-19 Vaccines, Moderna Memorandum to
Health Canada, and from the Ontario Ministry of Health COVID-19: Vaccine Storage and Handling Guidance
- Pfizer-BioNTech and Moderna COVID-19 Vaccines.
The storage and handling information differ depending on which presentation of the vaccine is considered.
For Pfizer storage and handling information refer to Home | CVDVACCINE
PURPOSE
The purpose of this Standard Operating Procedure (SOP) is to outline a process for redistribution of the
Pfizer BioNTech vaccine and the Moderna vaccine.
This SOP will provide guidelines for movement of the vaccine at 2 to 8°C.Vaccines are to be transported for
use at a clinic site, or for storage at a facility.
Potential redistribution example scenarios:
• Transport to long term care facilities (LTCF)
• Transport to an off-site or satellite clinic
• Transport to remote communities
• Transport to another site.
1. PROCESS
Vaccines can lose their potency if exposed to temperatures outside the recommended temperature range
for the specific product. Storage requirements for COVID vaccine products (ultra-low, frozen, and
refrigerated temperatures) are described below.
Staff at designated sites where vaccine is stored, i.e. hospital pharmacy sites or McKesson, are responsible
for preparing vaccine into smaller portable packaging for redistribution.
Department of Health is responsible for identifying requirements to the Regional Health Authorities for
redistribution such as shipping containers, temperature monitors, and packing guidelines that meet the cold
storage requirements for the vaccine; and for ensuring appropriate transporters have been selected for
redistribution of the vaccine. Department of Health is also responsible to ensure contingency plans are in
place, i.e. in the event of inclement weather or vehicle breakdown.
The Department of Health should be contacted if exceptional circumstances arise that warrant a process
not included in this standard operating procedure.
Planning Principles
The following principles are to be used for planning by the Department of Health and the Regional Health
Authorities before redistribution is considered. To see more information about current priority groups:
https://www2.gnb.ca/content/gnb/en/corporate/promo/covid-19/vaccine.html#strat
1. Secure Transportation: To ensure that vaccine wastage is minimized, it is critical that vaccine
potency is protected by maintaining cold chain at all times during transportation. Manufacturer
guidelines should be followed. (See details below)

1 November 2021
TRANSPORTATION OF COVID-19 VACCINES

2. Integrity: The main supply of vaccine should be housed at a facility with a Drug Establishment
License (DEL), i.e. with McKesson. It is recommended that all immunizers, clinic and pharmacies
continue to have contingency plans in place for any vaccine inventory.
3. Accessibility: Moving vaccine onward should be considered for all vaccines and across all
priority groups in at all stages to ensure that citizens have access to vaccination clinics in all
health zones at readily accessible clinic sites.
4. Equity: Vaccine should be distributed on a proportional basis as per determined vaccine
allocation that would provide coverage as per the eligibility at a given time in the vaccine roll out.
5. Consolidation: Consideration should be given to immunize on a location basis (i.e. vaccinate
an entire facility at once), where applicable and supported from a logistical perspective (i.e.
residents, workers and essential visitors in a single session - could be over several days if the
vaccine storage and use guidelines are adhered to).
6. Consistency: Best practice encourages clients to receive the same vaccine for first and second
dose where at all possible. Also, to minimize errors, clinic locations should have processes in
place if more than one vaccine product will be administered on site at the same time.
7. Redistribution: Vaccine uptake will be continuously monitored, and as such vaccine may be
required to be redistributed across the province. (i.e. if a zone has low uptake, it may be
distributed to another part of the province).
8. Reduce Wastage: To avoid wastage, vaccines that cannot be used at the clinic site should be
stored refrigerated at 2 to 8°C with a temperature monitoring device, min-max thermometer, with
the overall storage time recorded and monitored to ensure use of the vaccine within the approved
time.

1.1. Storage Requirements for COVID Vaccines

Storage Pfizer-BioNTech Pediatric Pfizer Moderna

Condition (Comirnaty for 12 (Comirnaty for 5 to less
years and up) than 12 years)
Frozen Vials • Keep between - • Keep between -80°C • Keep between -
Prior to Use 80°C to -60°C up to -60°C for up to 6 25°C to -15°C.
to 9 months months from the date • Protect from
• Can be stored at of manufacturer light.
-25°C to -15°C for printed on the vial. • Do not store on
two weeks. • Cannot be stored or dry ice or below
• Protected from transported at -20°C -40°C.
Light, in the to -15°C
original
packaging, until
ready to use.
Thawed, • Prior to dilution, • Prior to dilution, the • If not punctured,
unpunctured the vaccine may vaccine may be the vaccine
vials be thawed and thawed and stored at should be
stored at +2°C to +2°C to thawed and
+8°C for up to 31 +8°C for up 10 weeks stored at
days (one month) or at room +2°C to 8°C for
or at room temperature (up to up to 30 days,
temperature (up 25 °C) no more than or at +8°C to
to 12 hours. +25°C for up to
+25°C) no more • During storage and 24 hours.
than 2 hours. handling, minimize • During storage,
• During storage, exposure to room vials should be

November 2021 2
TRANSPORTATION OF COVID-19 VACCINES

minimize light, and avoid protected from

exposure to room exposure to direct light.
light, and avoid sunlight and • Do not refreeze
exposure to direct ultraviolet light. thawed vials.
sunlight and • Do not refreeze
ultraviolet light. thawed vials.
• Thawed vials can
be handled in
room light
conditions.
• Do not refreeze
thawed vials.
Thawed, • After dilution, the • After dilution, the • The vaccine
punctured vaccine should vaccine should be should be
vials be stored stored between +2°C stored between
between +2°C to to +25°C and used +2°C to below
+25°C and used within 12 hours from +25°C and used
within 6 hours the time of dilution. within 24 hours
from the time of • During storage, from the time of
dilution. minimize exposure to fist puncture.
• During storage, room light, and avoid • During storage,
minimize exposure to direct vials should be
exposure to room sunlight and protected from
light, and avoid ultraviolet light. light.
exposure to direct • After dilution, the
sunlight and vaccine vials can be
ultraviolet light. handled in room light
• After dilution, the conditions.
vaccine vials can
be handled in
room light
conditions.
Redistribution • Transport full • Transport full cartons • Transport
trays at at cartons or
-80°C to -60°C or -80°C to -60°C or 2- individual vials
-25°C to -15°C or 8°C. in the frozen
2-8°C • Transport individual state at -25°C
• Transport vials at 2-8°C (no to -15°C
individual vials at limit in transportation • Transport
25°C to -15°C time) cartons or
• Transport individual vials
individual vials at at 2-8°C
2-8°C ( maximum (maximum 12
12 hours hours
transportation transportation
time) time)
For more information, consult the product leaflet or information contained
within the product monograph available through COVID-19 vaccines and
treatments portal (canada.ca)Refer to Storage and Handling of Immunizing
Agents in the Canadian Immunization Guide (CIG), Part 1 – Key
Immunization for additional general information.

3 November 2021
TRANSPORTATION OF COVID-19 VACCINES

1.2. Guidelines for Redistribution

Pfizer BioNTech COVID-19 Vaccine
Redistribution guidelines differ depending on which presentation of the vaccine is considered.
For Pediatric Pfizer storage and handling information refer to Home | CVDVACCINE
The Pfizer BioNTech COVID-19 vaccine can be moved in the ultra- frozen state using the thermal
shipper and dry ice as per Pfizer’s guidelines. See https://www.cvdvaccine.ca/ for more information.
Note: Dry ice is a hazardous material and requires special handling

Movement in ultra-frozen state

• Only full trays (195 vials per tray) or full cartons (100 doses).
• Trays that arrive in ultra frozen condition - which are kept closed- should not be at room
temperature for longer than 5 minutes.
• Before repacking the vials into another thermal shipping container for transport, ensure the vials
have been stored at -90 to -60°C (ULT freezer or Pfizer thermal shipper) before transferring to
new container.
• If transporting in a container with dry ice, avoid direct contact of paperboard materials with dry ice.
Vials should never be in direct contact with dry ice.
• Avoid liquid nitrogen as a coolant, which can damage the vials and stoppers.
• If vials are removed from frozen conditions, they should be transported at refrigeration
temperatures (2-8 °C).
Movement at 2 to 8 degrees Celsius
• Vaccine can be transported as individual vials or full trays or cartons.
• Vaccine can be transported for secondary storage at another facility.
• Care must be taken to minimize extra movement in the thawed state.
• Ensure that only the number of frozen doses of the vaccine needed for the clinic are removed from
the storage unit to prevent unnecessary or accidental wastage.
• It is recommended that the vaccine is packed for delivery from ULT storage to be transported to
the clinic site in an insulated container/cooler at 2 to 8 degrees Celsius. See packing instructions.
• The vaccine cannot be transported at room temperature unless in prefilled syringes as per
Exceptional Circumstances Policy: Pre-filling syringes for onward transportation COVID-19
vaccines.
• Diluents should be transported with their corresponding vaccine (as per storage requirements) so
there are always equal amounts of vaccines and diluents for reconstitution.
• For the Pfizer vaccine for 12 years and up:
o vials should be transported to ensure destination is reached before the manufacturer’s
recommendation from Pfizer that states: Vials can be transported at this 2 to 8°C
temperature for up to 12 hours.
o Once vials have reached their destination, they can be stored between 2 to 8 degrees
Celsius for up to 31 days (1 month).The transportation time should be included as part
of the total allowable 31 days of product stability at 2 to 8°C, even if the vaccine is
frozen when placed in the cooler.

November 2021 4
TRANSPORTATION OF COVID-19 VACCINES

o If using 2 to 8°C for transportation, vials can be moved again as long as total
transportation time does not exceed 12-hours and that all above standards are
followed.
• For the Pfizer pediatric 5 to 11 years:
o There is no limit on transportation time at 2 to 8 degrees Celsius.
o Unpunctured vials can be stored at 2 to 8 degrees Celsius for up to 10 weeks.

Moderna COVID-19 Vaccine

The Moderna COVID-19 vaccine should be shipped in the frozen state at -25°C to -15°C.The
manufacturer indicates that transport of the Moderna vaccine may occur under certain circumstances
at 2°C to 8°C in which frozen state transport is not feasible.
Movement in the frozen state
• The vaccine must not be shipped or stored below -40°C or on dry ice.
• The long-term storage condition for the vaccine is -20°C ± 5°C (i.e. -25º to -15ºC) until expiration
date.
• Once a vial of the vaccine has been thawed, it may be kept at 2°C to 8°C for up to 30 days.
• Unpunctured vials may be stored between 8°C and 25°C for up to 24 hours, after which the product
must be discarded, unless placed back in the fridge at 2°C to 8°C.
• Once the vial has been entered (needle-punctured), it can be stored at room temperature or
refrigerated, but must be discarded after 24 hours
• A cumulative exposure up to 24 hours to temperatures between 8°C to less than or equal to 30°C
is allowed.
• Once thawed, the product cannot be refrozen.
Movement at 2°C to 8°C
• Available data support transportation of one or more thawed vials in liquid state for up to 12 hours
at 2° to 8°C when shipped using shipping containers which have been qualified to maintain 2° to
8°C and under routine road and air transport conditions with shaking and vibration minimized.
• The vaccine should be handled with care and protected as much as possible from shocks, drops,
vibration, etc.
• The transport container should be labeled prominently with “Fragile: Handle with Care, Do Not
Drop” cautionary statements.
• The transport containers must be secured (strapped/braced) when being transported to prevent
unnecessary movement.
• The vaccine should always be transported in insulated containers.
• The transport container should be labeled prominently with cautionary statements that it contains
vaccine and requires temperature control to prevent refreezing.
• Do not refreeze the vaccine during transport.
• The vaccine should be transported in the carton configuration wherever possible.
• The carton should be surrounded by dunnage (padding material) inside the container to minimize
product/carton movement during transport.
• If transport must be conducted at the vial level, the vial should be placed in insulation and bubble
wrap or similar padding to protect the product.

5 November 2021
TRANSPORTATION OF COVID-19 VACCINES

• Containers, cartons, and vials of the vaccine must be protected from being dropped.
• Punctured vials should not be transported.
• If using 2 to 8°C for transportation, vials can be moved again as long as the total transportation
does not exceed a 12-hour period, and that all above standards are followed.

2. RECOMMENDATIONS FOR ONWARD TRANSPORTATION

Caution should be taken to minimize shaking or agitation of the vaccine during transportation.
2.1. Packing for Just in time Use
The Department of Health will provide, via Service New Brunswick distribution, insulated containers
which are qualified to maintain 2 to 8°C use by the manufacturer, required packing materials such as
gel packs and bubble wrap, and temperature monitoring devices such as temp tales to sites that
require these, i.e. hospital pharmacies. Labels will be provided to document details: date and time
removed from ultra-low or frozen temperature.
• Transport all vaccines in insulated containers capable of maintaining the vaccine at the required
temperatures for the required duration for transportation and/or storage.
• Use a digital temperature monitoring device for all insulated containers used for transporting
vaccines.
• If vaccine requires dilution (Pfizer vaccine), vials must be transported undiluted. Do not transport
vials after dilution.
• For Pfizer, do not open the vial trays or cartons, or remove vials until you are ready for thawing
or use.
o Closed-lid vial trays or cartons containing from ultra-frozen storage (-80 to -60 °C) may be at
room temperature (less than 25°C) for up to 5 minutes for transfer between ultra- low
temperature environments.
o Repacking should be done in a 2°C to 8°C environment whenever possible. Otherwise, time
at room temp should be tracked and minimized.
o For Pfizer for 12 years and over, time at room temperature should be tracked to stay within
the 2-hour allowance for room temperature.
o For Pfizer for 12 years and over, if packing frozen (-25 to -15°C):Once trays are stored at -
25°C to -15°C (-13°F to 5°F), full trays should not be at room temperature for more than 3
minutes.
o Open- trays or vial trays containing less than 195 vials should not be at room temperature for
more than 1 minute. If vials are repackaged, time at room temperature should be minimized
as much as possible.
o Any hours used for transport at -25°C to -15°C count against the 2-week limit for storage at -
25°C to -15°C.
o After vial trays are returned to frozen storage, following room temperature exposure, they must
remain in frozen storage for at least 2 hours before they can be removed again.
o Once an individual vial is removed from a vial tray at room temperature, it cannot be returned
to frozen storage and should be thawed for use.
• Vials must be securely packed for transportation.
• Keep the vaccine vials upright and do not expose to light.
• Place in appropriate size box or tray; for example, box or tray the vaccine came in if available.

November 2021 6
TRANSPORTATION OF COVID-19 VACCINES

• Surround the vaccine with padding material (bubble wrap) to prevent movement
• For smaller shipments, single vials should be bubble wrapped before placing in a box or pill bottle,
using supplies that are already available.
• Do not allow vaccines to come in contact with frozen packs added to the cooler to maintain
temperature.
• Insulated vaccine containers, such as Cryopak coolers, should be prepared as per manufacturer’s
instructions.
• Label the date and time the vaccine is removed from frozen storage as the start time of the total
hours outside the frozen state on labels and attach to the vial or box of vials where it is visible to
receiver when cooler is unpacked.
• Vaccine should be handled with care and protected from shocks, drops, and vibration as much as
possible.
2.2. How to Pack an Insulated Cooler

• Follow insulated container detailed packing instructions for packing the vaccine at 2 to 8°C.
• Insulated vaccine containers, such as Cryopak coolers, should be prepared as per manufacturer’s
instructions. Payload refers to vaccine. See Appendix A.
• Insert a digital temperature monitoring device in the container. A device such as a temp tale or
min- max thermometer must be used for transporting vaccines. See Appendix B Temp Tales I mini
USB Pharma.
• Condition gel packs and the insulated container prior to use by:
o Placing gel packs at 2 to 8°C in the fridge for 24 hours prior to use.
o Store the insulated container at room temperature 24 hours prior to use.
• Clearly mark all insulated containers storing vaccines in a visible location with the following label:
“VACCINES – FRAGILE- DO NOT DROP.
Safe transfer
Designated delivery sites will be notified with transporter information if vaccine will be picked up by a
transporter. Coordination of date and time of pick up of the vaccine and estimated delivery time at
receiving site must be done prior to clinic date. The Transporter Register COVID-19 Vaccines is used
for confirmation and documentation of the transporter. See Appendix C.
2.3. Transportation to and arrival at clinic site
• Vaccine should be transported by designated persons aware of cold chain monitoring or couriers
who specialize in cold chain transport.
• Vaccine should be handled with care and protected from shocks, drops, and vibration as much as
possible.
• The container must be secured in the vehicle to prevent it from moving around.
• The temperature within the vehicle should not be outside room temperature 15ºC to 20ºC.
• Do not expose vaccines to extreme heat or cold during transport. Vaccines in insulated containers
should be placed in the area of the vehicle that maintains room temperature; i.e. not the trunk of
a car.

7 November 2021
TRANSPORTATION OF COVID-19 VACCINES

2.4. Receipt of the vaccine

The receiving site must:
• Designate the lead/alternate for the clinic site who will be an authorized receiver of the vaccine
delivery. This individual should ensure that standard operating policies and procedures related to
vaccine storage and handling are in place and are followed.
• Ensure that responsible staff are adequately trained and have knowledge of the requirements for
vaccine storage and handling, product sensitivities, storage equipment, temperature monitoring
devices, and inventory management procedures.
• Ensure that designated lead/ alternate(s):
o Are available to receive and store vaccines when they are expected to arrive;
o Never leave vaccines in a shipping container, unpacked or unattended;
o Understand that vaccine deliveries require immediate attention;
• Upon arrival at the clinic site the staff person who receives the vaccine:
o Immediately opens all of the transport containers and assess the digital temperature monitoring
device(s).
o Confirms the digital temperature monitoring device(s) indicates that the cold chain was
maintained between +2ºC to +8ºC during transport.
o Examines the shipment for evidence of damage and seek advice immediately if damaged. See
below.
o Documents their name, the date and time of receipt of the vaccines and signs the Receipt of
Vaccines Register Appendix D to acknowledge the receipt of the vaccines. If the vaccines were
received at a refrigerated temperature (i.e., between 2°C to 8°C), document the amount of time
remaining from cumulative refrigerated storage conditions (i.e., Pfizer = 31 days; Moderna =
30 days).
o Ensures the number of doses of vaccine to be used immediately should be thawed at the clinic
location according to the manufacturer specifications and the rest stored at 2 to 8°C prior to
dilution if required.
• Once thawed, the vaccine cannot be refrozen.
• To avoid wastage, vaccines that cannot be used at the clinic site should be stored refrigerated at
2 to 8°C with a temperature monitoring device, min-max thermometer, with the overall storage
time recorded and monitored to ensure use of the vaccine within the approved time.
• The cooler or Credo must be returned as per distributor’s instructions and recorded on the Receipt
of Vaccines Register.
2.5. Temperature excursions
Sites storing publicly funded vaccine should have an operational plan in place in the event of a
power failure. Refer to NBIPG-appendice5-4.pdf (gnb.ca) Guidance for Vaccine Response Plan in
the event of power failure
A Vaccine Command Centre has been created to address vaccine concerns, i.e. shipment issue,
power outages, vaccine excursions, etc.
To contact the Vaccine Operation Control Center: Email: [email protected] Telephone: 833-
414-2369
When a temperature excursion occurs during transportation to a site, notify Regional Public Health
immediately. See Appendix E for contact information during routine business hours:

November 2021 8
TRANSPORTATION OF COVID-19 VACCINES

Regional Public Health will advise the Department of Health (DOH) by contacting Vaccine Operation
Control Center using the following reporting format:
• Subject: Delivery Temp Excursion Report
o Date of Incident
o Vaccine Delivery Site (VDS) Location
o Number of doses impacted by the excursion
o Wastage (number of doses or indicate no wastage)
o Impact on local vaccination efforts
During afterhours:
Regional Public Health will advise the Department of Health (DH) by contacting the Vaccine Operation
Control Center:
Email: [email protected]
The DOH will contact:
• Pfizer: Contact Pfizer Customer Service at 1-833-829-2684 or [email protected].
• Moderna: Contact Innomar QA at 1-833-847-4270 or QA-GMP@innomar - strategies.com.
• The National Operating Centre to advise of the incident, resolution and any impact on provincial
vaccination efforts.

RESOURCES
Canadian Immunization Guide (CIG), Part 1 – Key Immunization for additional general information
New Brunswick Immunization Program Guide Standard 3.4 – Vaccine Storage and Handling
National Vaccine Storage and Handling Guidelines for Immunization Providers, 2015
Pfizer-BioNTech Covid-19 Vaccine: https://www.cvdvaccine.ca/
Pfizer-BioNTech COVID-19 Vaccine (tozinameran) | COVID-19 vaccines and treatments portal (canada.ca)
Canada | Moderna COVID-19 Vaccine Information (modernacovid19global.com)
COVID-19 Vaccine Moderna (mRNA-1273 SARS-CoV-2) | COVID-19 vaccines and treatments portal
(canada.ca)

9 November 2021
APPENDIX A – PACKING INSTRUCTIONS SMALL

APPENDIX A – PACKING INSTRUCTIONS SMALL

November 2021 10
APPENDIX A – PACKING INSTRUCTIONS SMALL

11 November 2021
APPENDIX A – PACKING INSTRUCTIONS SMALL

12 November 2021
APPENDIX B – PACKING INSTRUCTIONS MEDIUM

APPENDIX B – PACKING INSTRUCTIONS MEDIUM

November 2021 13
APPENDIX B – PACKING INSTRUCTIONS MEDIUM

14 November 2021
APPENDIX C – TRANSPORTER REGISTER COVID-19 VACCINES

APPENDIX C – TEMP TALES IMINI USB PHARMA

Plug & Play USB Data Logger - iMini USB PDF (cryopak.ca)

November 2021 15
APPENDIX D –TRANSPORTER REGISTER COVID-19 VACCINES

APPENDIX D – TRANSPORTER REGISTER COVID-19 VACCINES

COVID19 VACCINE TRANSPORT REGISTER - HOSPITAL PHARMACY USE
Hospital name: ________________________________________

Date y/m/d Time Vaccine Destination Time picked Name of Identification Pharmacy Credo cube return date
arrived up transporter/ (employee card Staff signature and time
or drivers license
number/

Date:
Time:

Date:
Time:

Date:
Time:

Date:
Time:

Date:
Time:

Date:
Time:

Date:
Time:

16 November 2021
APPENDIX E – RECEIVER REGISTER COVID-19 VACCINES

APPENDIX E – RECEIVER REGISTER COVID-19 VACCINES

VACCINE RECEIPT OV COVID-19 VACCINE REGISTER – CLINIC SITE USE
Clinic site: __________________________________

Date y/m/d Time Document Amount of time Note time Number of Clinic Lead Staff Cooler or Credo
Vaccine time on label remaining vaccine started doses signature cube return date
arrived vaccine from room at room and time
started cumulative temperature temperature
refrigerated refrigerated
storage at 2- storage Note on label
8°C condition at 2- (Pfizer= 2
8°C hours;
(i.e., Pfizer = Moderna =
31 days;
Moderna = 30
days)

Date :
Time :

Date :
Time :

Date :
Time :

Date :
Time :

November 2021 17
ANNEXE B – DIRECTIVES D’EMBALLAGE, MOYENNE TAILLE

APPENDIX F – PUBLIC HEALTH COMMUNICABLE DISEASE TEAM CONTACT LIST

Contact information for the RHA Public Health Offices is listed below and is also available on the Office of
the Chief Medical Officer of Health’s website:
https://www2.gnb.ca/content/gnb/en/departments/ocmoh/healthy_people/content/public_health_clinics.ht
ml
Department of Public Safety Public Health Regional Health Authority Public Health
Inspectors Nurses
Central Region Zone 3
Fredericton (Regular hours): Fredericton (Regular hours):
Main office (506) 453-2830 Main office (506) 453-5200
Communicable Disease Line (506) 444-5905 Communicable Disease Line (506) 444-5905
Central Region After Hours Emergency Number 1-506-453-8128
South Region Zone 2
Saint John (Regular hours): Saint John (Regular hours):
Main office (506) 658-3022 Main office (506) 658-2454
Communicable Disease Line (506) 658-5188 Communicable Disease Line (506) 658-5188
South Region After Hours Emergency Number 1-506-658-2764
East Region Zone 1
Moncton (Regular hours): Moncton (Regular hours):
Main office (506) 856-2814 Main office (506) 856-2401
Communicable Disease Line (506) 856-3220 Communicable Disease Line (506) 856-3220

Zone 7
Miramichi (Regular hours):
Main office (506) 778-6756
Communicable Disease Line (506) 778-6104
East Region After Hours Emergency Number 1-506-856-2004
North Region Zone 4
Edmundston (Regular hours): Edmundston (Regular hours):
Main office (506) 737-4400 Main office: (506) 735-2065
Communicable Disease Line: (506) 735-2626

Campbellton (Regular hours): Zone 5

Main office (506) 789-2549 Campbellton (Regular hours):
Main office phone number: (506) 789-2266
Communicable Disease Line (506) 790-4769

Bathurst (Regular hours): Zone 6

Main office (506) 549-5550 Bathurst (Regular hours):
Main office phone number: (506) 547-2062
Communicable Disease Line (506) 547-2062
North Region After Hours Emergency Number 1-506-789-2428
Note: Regular hours are 8:15 am - 4:30 pm Monday-Friday.
The after-hours emergency number is to report notifiable diseases after 4:30 pm on weekdays and
on the weekends and holidays. The pager is intended for emergency reporting only and users are
asked to keep the after-hours pager number confidential within the facility (only for operators and
staff).

18 November 2021